Pfizer-BMS and Fitbit collaborate to develop devices to detect atrial fibrillation
The Bristol-Myers Squibb-Pfizer Alliance and Fitbit announced today that they are working in a strategic collaboration to develop devices that can detect atrial fibrillation, aim is to develop software that can detect the stroke in patients who are at risk. The companies are collaborating to give information on the software to the patients upon submission to the US Food and Drug Administration (FDA).
“We’re in a new era of healthcare, where we’re not only focused on developing treatments but also looking at the potential of technology and data to help patients learn more about their health,” said Angela Hwang, Group President, Pfizer Biopharmaceuticals Group.
As per the company statement, there are around eight million patients are suffering from AFib in the United States. Adults aged 65 years and old are at increased risk of AFib.
Wearable technology has continued increased and became an integral part of the patients.